OpenAI Acquires Orchestra Bio to Accelerate AI-Driven Drug Development
Sign in✓ Signed in
OpenAI has acquired Orchestra Bio, a startup building AI agents to streamline pharmaceutical research operations, marking the latest major move in a growing competition between AI labs to dominate drug discovery. The acquisition, announced October 20, was reported by Axios, with financial terms undisclosed.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...